MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
EVMN — Evommune, Inc.
NYSEEvommune, Inc.
$6.92
-0.29(-4.02%)
- O
- 7.25
- H
- 7.28
- L
- 6.74
- V
- 1.74M
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About EVMN
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateNov 6, 2025
Employees48
Stock ExchangeNYSE
Ticker SymbolEVMN
Websitehttps://www.evommune.com
Key Financial Statistics
| Market Cap | $251.14M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $6.74 - $33.20 |
| 52-Week Avg Volume | 580.3K |
| VWAP | $6.90 |
| Transactions | 14,515 |
| Total Recorded Bars | 227 days |